Presentation is loading. Please wait.

Presentation is loading. Please wait.

Skin Tumour Group National Perspective

Similar presentations


Presentation on theme: "Skin Tumour Group National Perspective"— Presentation transcript:

1 Skin Tumour Group National Perspective
Data from Portfolio ODP – Cut off 11/10/15

2 Skin Tumour Group National Perspective
Network 2014/2015 2015/2016 Commercial Non-Commercial Total Rank East Midlands 9 12 21 11 14 Eastern 56 27 83 2 30 Greater Manchester 8 6 23 4 Kent, Surrey and Sussex 3 7 1 13 North East and North Cumbria North Thames 10 17 15 5 North West Coast 63 76 North West London South London 42 44 South West Peninsula 19 Thames Valley and South Midlands 28 25 Wessex 34 West Midlands West of England 31 33 Yorkshire and Humber 219 253 53 57 Data from Portfolio ODP – Cut off 11/10/15

3 Skin Tumour Group Open Studies
Study EM E GM KSS NE&NC NT NWC NWL SL SWP TV&SM Wes WM WoE Y&H CANC Nivolumab for Subjects with Histologically Confirmed Stage III or Stage IV Melanoma 8 12 6 10 2 4 CANC VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE MALIGNANCIES 1 3 EORTC Adjuvant Pegylated Interferon in Ulcerated Melanoma Head and neck skin malignancy 57 MelMarT - Melanoma Margins Trial - Pilot Study 30 7 5 NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma 13 NCRN567 COLUMBUS: LGX818 +/- MEK162 vs vemurafenib in BRAF V600 melanoma Paclitaxel +/- GSK or Pazopanib in Melanoma - PACMEL 14 21 SPOT Trial 18 27 UKMCC-01 9 UNITI (Version 2.1) 42 Vitamin D & Immunity Study. Version 3.0 266 WBRT post local treatment in melanoma study Data from Portfolio ODP – Cut off 11/10/15

4 Skin Tumour Group SWP Recruitment
Data from Portfolio ODP – Cut off 11/10/15

5 Skin Tumour Group SWP Recruitment
Trust 2014/2015 2015/2016 Commercial Non-Commercial Total Northern Devon Healthcare NHS Trust Plymouth Hospitals NHS Trust 4 Royal Cornwall Hospitals NHS Trust 11 Royal Devon and Exeter NHS Foundation Trust 1 2 Taunton and Somerset NHS Foundation Trust 3 Torbay and South Devon NHS Foundation Trust Yeovil District Hospital NHS Foundation Trust Data from Portfolio ODP – Cut off 11/10/15

6 Skin Tumour Group RAG Report
Acronym UKCRNID Study Type Trust Investigator Name Recruitment End Date Planned Target Recruitment (Edge) RTT CANC Nivolumab (BMS ) in Stage III (unresectable) or stage IV Melanoma (CA ) 17463 Commercial RCHT Talbot, Dr Toby 22-Dec-19 3 83 NCRN398 IMAGE: Observational Study in Patients with Unresectable or Metastatic Melanoma 12088 28-Mar-15 54 27 -69 NCRN492 - NEMO-MEK162 vs Dacarzabine in NRAS mutation postive melanoma patients 13665 31-Mar-15 -43 UKMCC-01 13736 Non-Commercial RD&E Goodman, Dr Andrew 01-Aug-19 2 1 19 T&S Barthakur, Urmila -30 Data from EDGE– Cut off 06/10/15


Download ppt "Skin Tumour Group National Perspective"

Similar presentations


Ads by Google